Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
- سال انتشار: 1397
- محل انتشار: فصلنامه آسیب شناسی ایران، دوره: 13، شماره: 1
- کد COI اختصاصی: JR_IJP-13-1_009
- زبان مقاله: انگلیسی
- تعداد مشاهده: 393
نویسندگان
Hematology and Oncology Division, Dept of Internal medicine, Afzalipour Kerman Medical Science University, Kerman, Iran
Pathology and Stem Cells Research Center, Dept of Pathology, Afzalipour Kerman Medical Science University, Kerman, Iran
Hematology and Oncology Division, Dept of Internal medicine, Afzalipour Kerman Medical Science University, Kerman, Iran
Hematology and Oncology Division, Dept of Internal medicine, Afzalipour Kerman Medical Science University, Kerman, Iran
چکیده
Background and objective:Breast cancer is the most common malignancy among women. The Neoadjuvant chemotherapy is the treatment of choice for non-operable tumors. The Ki67 is a proliferation marker that can be used to predict the therapeutic response to chemotherapy and the patients prognosis. Methods: This retrospective study was carried out on 55 consecutive patients with breast cancer referred to a Training Tertiary Healthcare Center in Kerman, Iran since 2009 to 2014. After diagnostic approval, the tissue samples of patients were examined for estrogen and progesterone receptors, ki67 and HER2-neu markers by using immunohistochemical staining. Then the patients were treated with 6 cycles of Neoadjuvant chemotherapy regimens by Doxorubicin and Taxans or 4 chemotherapy cycles, containing Anthracycline and Cyclophosphamide and 4 cycles of Paclitaxel. After mastectomy, their samples were reexamined for ki67 again and classified into three groups (low: ki67< 15%), medium (Ki67 = 16-30%) and high (Ki67> 30%). Results: Before chemotherapy, 54.5% of the patients had high expression of Ki67. But after chemotherapy, 52.7 of the patients had complete therapeutic response showing that the Ki67 level was reduced significantly (P=0.003). Conclusion: Before and after Neoadjuvant chemotherapy, Ki67 measurements may be used as a predictive marker of therapeutic response.کلیدواژه ها
Neoadjuvant Therapy, Ki 67, Breast cancer, Prognosisاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.